Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.64 |
| ▸ | HTR3A | P46098 | 1/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2228214 | 1.00 | CHRNA7 (0.64) | CHRNA7HTR3AKCNH2 | |
| SCHEMBL7281094 | 1.00 | CHRNA7 (0.64) | CHRNA7HTR3AKCNH2 | |
| SCHEMBL9731329 | 0.90 | CHRNA7 (0.57) | CHRNA7 | |
| SCHEMBL9731338 | 0.90 | CHRNA7 (0.57) | CHRNA7 | |
| SCHEMBL9731634 | 0.90 | CHRNA7 (0.57) | CHRNA7 | |
| SCHEMBL7437115 | 0.89 | CHRNA7 (0.62) | CHRNA7HTR3AKCNH2 | |
| SCHEMBL7437131 | 0.89 | CHRNA7 (0.62) | CHRNA7HTR3AKCNH2 | |
| Hydrochloric Acid SCHEMBL7432786 | 0.88 | CHRNA7 (0.61) | CHRNA7HTR3AKCNH2 | |
| Hydrochloric Acid SCHEMBL7432776 | 0.88 | CHRNA7 (0.61) | CHRNA7HTR3AKCNH2 | |
| SCHEMBL2228414 | 0.86 | HTR3A (0.64) | CHRNA7HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0190920-B1 | METHOD OF ENHANCING MEMORY OR CORRECTING MEMORY DEFICIENCY WITH ARYLAMIDO (AND ARYLTHIOAMIDO)AZABICYCLOALKANES | SYNTHELABO (FR) | 1993-05-05 | — | — | EP | claimed |
| US-5206246-A | Anxiolytic agents | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-04-27 | — | — | US | claimed |
| EP-0306345-B1 | 2-ALKOXY-N-(1-AZABICYCLO(2.2.2)-OCT-3-YL) BENZAMIDES AND THIOBENZAMIDES HAVING AN ANTISCHIZOPHRENIC ACTIVITY | SYNTHELABO (FR) | 1993-04-14 | — | — | EP | claimed |
| EP-0327335-B1 | ARYLAMIDO(AND ARYLTHIOAMIDO)-AZABICYCLOALKANES FOR ENHANCING MEMORY OR CORRECTING MEMORY DEFICIENCY | SYNTHELABO (FR) | 1992-10-14 | — | — | EP | claimed |
| EP-0272052-B1 | Anxiolytic-N-(1-Azabicyclo[2.2.2]Oct-3-yl) Benzamides and Thobenzamides | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1992-07-08 | — | — | EP | claimed |
| US-4908370-A | Antianxiety agents | A. H. ROBBINS COMPANY, INC. (US) | 1990-03-13 | — | — | US | claimed |
| US-4863919-A | Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-09-05 | — | — | US | claimed |
| EP-0306345-A2 | 2-Alkoxy-n-(1-azabicyclo(2.2.2)-oct-3-yl) benzamides and thiobenzamides having an antischizophrenic activity | SYNTHELABO (FR) | 1989-03-08 | — | — | EP | claimed |
| EP-0272052-A1 | Anxiolytic-N-(1-Azabicyclo[2.2.2]Oct-3-yl) Benzamides and Thobenzamides | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1988-06-22 | — | — | EP | claimed |
| US-4717563-A | 2-alkoxy-N-(1-azabicyclo(2.2.2)oct-3-yl) benzamides and thiobenzamides in a method for alleviating emesis caused by non-platinum anticancer drugs | A. H. ROBINS COMPANY, INC. (US) | 1988-01-05 | — | — | US | claimed |
| EP-0240180-A1 | 2-alkoxy-N-(1-azabicyclo[2.2.2]-oct-3-yl) benzamides and thiobenzamides in the alleviation of emesis caused by non-platinum anticancer drugs | SYNTHELABO (FR) | 1987-10-07 | — | — | EP | claimed |
| EP-0190920-A2 | Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)azabicycloalkanes | SYNTHELABO (FR) | 1986-08-13 | — | — | EP | claimed |
| US-4605652-A | ALZHEIMER'S DISEASE; SENILITY | A. H. ROBINS COMPANY, INC. (US) | 1986-08-12 | — | — | US | claimed |
| EP-0158532-A2 | Use of 4-amino-N-(1-azabicyclo[2.2.2]oct-3-yl)-5-chloro-2-methoxybenzamide for the manufacture of a medicament having anti-emetic activity. | SYNTHELABO (FR) | 1985-10-16 | — | — | EP | claimed |
| EP-2344636-B1 | NOVEL CHIMERIC LIGAND-GATED ION CHANNELS AND METHODS OF USE THEREOF | HUGHES HOWARD MED INST (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-2344636-B1 | NOVEL CHIMERIC LIGAND-GATED ION CHANNELS AND METHODS OF USE THEREOF | HUGHES HOWARD MED INST (US) | 2017-12-06 | — | — | EP | disclosed |
| US-8435762-B2 | Chimeric ligand-gated ion channels and methods of use thereof | HOWARD HUGHES MEDICAL INSTITUTE (US) | 2013-05-07 | — | — | US | disclosed |
| US-4605652-A | ALZHEIMER'S DISEASE; SENILITY | A. H. ROBINS COMPANY, INC. (US) | 1986-08-12 | — | — | US | disclosed |
| US-4593034-A | 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides | A. H. ROBINS COMPANY, INC. (US) | 1986-06-03 | — | — | US | disclosed |
| EP-0158532-A2 | Use of 4-amino-N-(1-azabicyclo[2.2.2]oct-3-yl)-5-chloro-2-methoxybenzamide for the manufacture of a medicament having anti-emetic activity. | SYNTHELABO (FR) | 1985-10-16 | — | — | EP | disclosed |